## COMMONWE ALTH OF VIRGINIA Department of Health Professions 1601 Rolling Hills Drive

Richmond, Virginia 23229

DATE:
TIME:
MILEAGE:
INSPECTION HOURS:

## Manufacturer's Inspection Report

Fa	cility Name:		P	ermit No	Exp. Date
Ad	dress:			<del></del>	
	ner:				
Su	pervising Pharm.:			Lic. No	Exp. Date
**	******	****	****	*****	******
FA	CILITY:	YES	NO		DOCUMENTATION
1.	Required licenses properly displayed?				
SA	FEGUARDS AGAINST DIVERSION OF DRUGS:				
2.	Sound, microwave, photoelectric, ultrasonic, or other generally accepted device installed in each drug storage and manufacturing area?				
	a. Device maintained in operating order?				
	b. Device protects immediate drug storage and manufacturing area.				
	c. Device have auxiliary power source?				
	d. Storage area for Schedule II through V drugs restricted to a limited number of designated employees?				
	e. Reasonable measures taken to prevent pilfering of drugs from restricted area?				
DR	UG INVENTORY AND RECORDS:				
3.	Schedule II through V drug records maintained at facility for two years?				
4.	Required inventories of Schedule II through V drugs:				
	a. Biennial inventory?				
	(1) Inventory date:				
	(2) Opening of business:				
	(3) Close of business:				
	(4) Inventory Signedname		,		
5.	Inventories and records of Schedule II drugs maintained separately from all other records?				
6.	Inventories and records of Schedule III through V drugs maintained separately or with records of Schedule VI drugs?				
7.	Schedule II through V records maintained at same location as stock of drug to which records pertain?		·		
8.	Receipt of Schedule II through V drugs dated with the actual date of receipt?				<b>~</b>
9.	Schedule II distribution records maintained separately from other distribution records?				

		YES	NO	DOCUMENTATION
Dru	g Inventory and Records (cont.):	•		
10.	Schedule III through V distribution records maintained separately or filed with Schedule VI distribution records.		erates enterior	
11.	Distribution records include:		4	
	a. Date distributed?			
	b. Name and address of person receiving drug?			
	c. Name and strength of drug?			
	d. Quantity distributed?			
	e. Lot or control number?			
	f. Description of Dosage Form			
BU	ILDING AND FACILITIES:			
12.	Building contain defined areas to prevent mix-ups?			
13.	Defined areas include:			
	a. Quarantine area?			
	b. Storage area for rejected components?			,
	c. Storage area for released components?			
	d. Packaging and labeling area?			
	e. Control and laboratory area?			
	f. Separate area for processing penicillin products?			
14.	Facility maintained temperature maintained between 59–86°F? (Temperature)			
15.	Washing and toilet facilities include:			
	a. Hot and cold running water?		Marine State Control of the Control	
	b. Soap or detergent?			
	c. Air devices or single-service towels?			
	d. Toilet?			
SA	NITATION:			
16.	Facility clean and sanitary?			
17.	Written procedure for cleaning schedule?			
	Written procedure for use of insecticides and sanitizing agents?		·	
EQ	UIPMENT:			
	Equipment clean?			
`	Written procedure for maintaining and cleaning equipment?			
21.	Records maintained on cleaning and sanitizing equipment?	-		

## CONTROL OF COMPONENTS, DRUG PRODUCTS, CONTAINER AND CLOSURES:

	•		
22.	Written procedures describing receiving, identifying, storing, handling, sampling, and testing components?		<u> </u>
23.	Components, drug containers, and closures stored under quarantine until tested and released?		
24.	Records maintained of testing components prior to use?		
25.	Rejected components identified and controlled under a quarantine system?		
PR	ODUCTION AND PROCESSING CONTROLS:		
26.	Written procedures to assure drug products' identity, strength, quality, and purity?		
27.	Procedures include:		
	a. Charge-in components?		
	b. Calculations of yield?	<del></del>	
	c. Equipment identification?		
	d. Sampling and testing in-process materials and drug products?		
	e. Time limitations on productions?		
	f. Control of contamination?		
	g. Reprocessing and batching?		
PAC	CKAGING AND LABELING CONTROL:		
28.	Written procedures describing receiving, identifying, storing, handling, sampling, testing, and approving labels?		
39.	Procedures utilized to reconcile quantities of labels issued and used?		
30.	Excess labels bearing lot number destroyed?		
31.	Written procedures describing controls for issuing labels?		
32.	Written procedures to assure correct labels, labeling, and packaging are used?		
33.	Packaging and labeling products examined during finishing operations?		
34.	Samples collected at completion of finishing operation and visually examined?		
35.	Results of examination recorded?		

LA	BORATORY CONTROLS:	YES	NO
36.	Written procedures for sampling and testing?		
	Procedures include:	-	
	a. Determination for conformance for identity and strength of each active product?		
	b. Testing, as necesary, of each batch for microorganisms?		
38.	Written testing program to assess the stability of drug products?		
39.	Representative reserve sample of each lot or batch of drug retained?		
40.	Sample retained for one year after expiration date of last lot or batch?		
41.	Sample retained in same container in which product is marketed?		
RE	CORDS AND REPORTS:		
42.	Record maintained for equipment cleaning and use?		
<b>4</b> 3.	Master production and control records maintained for each batch of drug product?		
	a. Reproduction of master production or control record checked, dated, and signed?		
	b. Documentation that each step in the process was accomplished?		
	c. Records reviewed by quality control unit to determine compliance with written procedures?	-	
44.	Laboratory records maintained on all tests to assure compliance with all written procedures?		
<b>4</b> 5.	Complaint files maintained, which includes:		
	a. Written procedures for handling written and oral complaints?		
	b. Written record maintained in a file designated for drug product complaints?		
	c. Record maintained for one year after expiration date of product or after the date the complaint was received?		

## GENERAL REMARKS:

**DOCUMENTATION** 

ACTION TAKEN:				
(1)	New Inspection	(4)	Drug	Destruction
(2)	Routine Inspection		Drug	
(3)	Reinspection	(6)	Other	
				(Specify)
ACKNOWLEDGEMENT:				
This manufacturer has been ins I acknowledge that the noted co I have received a copy of this ins	onditions that have been deemed b	artment of Health by the inspector as	Professions. The results of the inspendent being in compliance have been ex	ection have been noted. cplained to me and that
Inspector/De	ept. of Health Professions)		D	
inspector (De	ept. of Health Frotessions)		Person in Charg	ge
Date		ne of Exit	Title of Authorized Individual	
*****	******	*****	******	*****
	FOR O	FICE USE ONL	Y	
Violations this inspection:	<del></del> ,			
Violations Previous Inspecatio	n:			
Repeated Violations:				
		-5-		
WHITE (ORIGINAL)-TO INSPE	ECTION UNIT YELLOW-TO P	ERMIT HOLDER	GREEN-TO INSPECTION UNIT	PINK-INSPECTOR

General Remarks (Continued):